Orbimed Advisors is an investment fund managing more than $4.99 trillion ran by Sven Borho. There are currently 108 companies in Mr. Borho’s portfolio. The largest investments include Sinovac Biotech and Biogen Inc, together worth $554 billion.
As of 7th February 2024, Orbimed Advisors’s top holding is 2,718,735 shares of Sinovac Biotech currently worth over $340 billion and making up 6.8% of the portfolio value.
Relative to the number of outstanding shares of Sinovac Biotech, Orbimed Advisors owns more than approximately 0.1% of the company.
In addition, the fund holds 827,600 shares of Biogen Inc worth $214 billion, whose value fell 16.9% in the past six months.
The third-largest holding is Eli Lilly & Co worth $213 billion and the next is Boston Scientific worth $191 billion, with 3,306,800 shares owned.
Currently, Orbimed Advisors's portfolio is worth at least $4.99 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Orbimed Advisors office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Sven Borho serves as the Member at Orbimed Advisors.
In the most recent 13F filing, Orbimed Advisors revealed that it had opened a new position in
Eli Lilly & Co and bought 365,400 shares worth $213 billion.
The investment fund also strengthened its position in Biogen Inc by buying
603,000 additional shares.
This makes their stake in Biogen Inc total 827,600 shares worth $214 billion.
Biogen Inc dropped 21.6% in the past year.
On the other hand, there are companies that Orbimed Advisors is getting rid of from its portfolio.
Orbimed Advisors closed its position in Bristol-Myers Squibb Co on 14th February 2024.
It sold the previously owned 2,584,900 shares for $184 million.
Sven Borho also disclosed a decreased stake in Boston Scientific by 0.2%.
This leaves the value of the investment at $191 billion and 3,306,800 shares.
The two most similar investment funds to Orbimed Advisors are Copeland Capital Management and Financial Counselors Inc. They manage $4.99 trillion and $5 trillion respectively.
Orbimed Advisors’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 66.3% of
the total portfolio value.
The fund focuses on investments in the United States as
54.6% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
19% of the total holdings value.
On the other hand, small-cap stocks make up only 7.4% of the portfolio.
The average market cap of the portfolio companies is close to $29 billion.
These positions were updated on February 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Sinovac Biotech Ltd. |
No change
2,718,735
|
$340,000,000,000 | 6.81% |
| Biogen Inc |
268.48%
827,600
|
$214,158,052,000 | 4.29% |
| Eli Lilly & Co |
Opened
365,400
|
$212,998,968,000 | 4.27% |
| Boston Scientific Corp. |
15.17%
3,306,800
|
$191,166,108,000 | 3.83% |
| Intuitive Surgical Inc |
12.87%
499,000
|
$168,342,640,000 | 3.37% |
| Edgewise Therapeutics Inc |
No change
14,567,176
|
$159,364,905,000 | 3.19% |
| Biomarin Pharmaceutical Inc. |
8.50%
1,571,410
|
$151,515,352,000 | 3.03% |
| Rayzebio Inc |
Opened
2,365,213
|
$147,045,292,000 | 2.95% |
| Enliven Therapeutics Inc |
Opened
8,998,338
|
$124,536,998,000 | 2.49% |
| SpringWorks Therapeutics, Inc. |
41.74%
3,219,359
|
$117,506,604,000 | 2.35% |
| Merck & Co Inc |
Opened
1,055,000
|
$115,016,100,000 | 2.30% |
| Ionis Pharmaceuticals Inc |
168.54%
2,064,797
|
$104,458,080,000 | 2.09% |
| Disc Medicine Inc |
Opened
1,702,237
|
$98,321,209,000 | 1.97% |
| Gracell Biotechnologies Inc. |
18.06%
9,308,726
|
$93,459,609,000 | 1.87% |
| Tenet Healthcare Corp. |
90.33%
1,224,400
|
$92,527,908,000 | 1.85% |
| Evolent Health Inc |
37.69%
2,746,532
|
$90,717,952,000 | 1.82% |
| United Therapeutics Corp |
Opened
386,100
|
$84,899,529,000 | 1.70% |
| Xtant Med Hldgs Inc |
No change
73,114,592
|
$82,619,489,000 | 1.65% |
| Stryker Corp. |
36.42%
269,000
|
$80,554,740,000 | 1.61% |
| Scholar Rock Hldg Corp |
535.53%
4,245,000
|
$79,806,000,000 | 1.60% |
| Thermo Fisher Scientific Inc. |
28.88%
143,800
|
$76,327,602,000 | 1.53% |
| Verona Pharma Plc |
33.66%
3,777,778
|
$75,102,227,000 | 1.50% |
| Vaxcyte, Inc. |
60.62%
1,153,091
|
$72,414,115,000 | 1.45% |
| Theseus Pharmaceuticals Inc |
3.94%
17,713,600
|
$71,740,080,000 | 1.44% |
| Vertex Pharmaceuticals, Inc. |
53.05%
175,200
|
$71,287,128,000 | 1.43% |
| Neurocrine Biosciences, Inc. |
42.08%
519,279
|
$68,420,201,000 | 1.37% |
| Sarepta Therapeutics Inc |
24.06%
697,500
|
$67,259,925,000 | 1.35% |
| Elevance Health Inc |
Opened
141,500
|
$66,725,740,000 | 1.34% |
| Third Harmonic Bio Inc |
No change
5,779,071
|
$63,396,409,000 | 1.27% |
| Natera Inc |
36.59%
954,481
|
$59,788,690,000 | 1.20% |
| Crinetics Pharmaceuticals In |
47.84%
1,667,360
|
$59,324,669,000 | 1.19% |
| Apellis Pharmaceuticals Inc |
Opened
922,200
|
$55,202,892,000 | 1.11% |
| R1 RCM Inc. |
Opened
4,803,200
|
$50,769,824,000 | 1.02% |
| Ars Pharmaceuticals Inc |
5.72%
9,240,887
|
$50,640,061,000 | 1.01% |
| Keros Therapeutics, Inc. |
24.45%
1,268,734
|
$50,444,864,000 | 1.01% |
| Humana Inc. |
68.48%
109,900
|
$50,313,319,000 | 1.01% |
| Terns Pharmaceuticals Inc |
1.84%
7,619,135
|
$49,448,186,000 | 0.99% |
| Alpine Immune Sciences Inc |
37.89%
2,535,245
|
$48,321,770,000 | 0.97% |
| SI-BONE Inc |
31.93%
2,292,531
|
$48,120,226,000 | 0.96% |
| Prelude Therapeutics Inc |
8.66%
10,909,256
|
$46,582,523,000 | 0.93% |
| ALX Oncology Holdings Inc. |
7.80%
3,095,000
|
$46,084,550,000 | 0.92% |
| Neuropace Inc |
0.21%
4,003,967
|
$41,280,900,000 | 0.83% |
| Iovance Biotherapeutics Inc |
134.50%
4,707,458
|
$38,271,634,000 | 0.77% |
| Syndax Pharmaceuticals Inc |
12.83%
1,749,000
|
$37,795,890,000 | 0.76% |
| Icon Plc |
Opened
132,200
|
$37,421,854,000 | 0.75% |
| Unitedhealth Group Inc |
73.80%
70,000
|
$36,852,900,000 | 0.74% |
| Ikena Oncology Inc |
3.36%
15,588,131
|
$43,773,045,000 | 0.88% |
| AMGEN Inc. |
Opened
127,300
|
$36,664,946,000 | 0.73% |
| Apogee Therapeutics Inc |
Opened
1,277,901
|
$35,704,554,000 | 0.72% |
| Janux Therapeutics Inc |
16.98%
3,317,927
|
$35,601,357,000 | 0.71% |
| Compass Therapeutics Inc |
1.83%
22,362,850
|
$34,886,046,000 | 0.70% |
| scPharmaceuticals Inc |
15.89%
5,559,528
|
$34,858,241,000 | 0.70% |
| Argenx Se |
68.63%
84,600
|
$32,184,378,000 | 0.64% |
| Fusion Pharmaceuticals Inc. |
3.16%
3,122,770
|
$30,009,820,000 | 0.60% |
| Acelyrin Inc |
Opened
4,001,711
|
$29,852,764,000 | 0.60% |
| Neumora Therapeutics Inc. |
Opened
1,500,000
|
$25,575,000,000 | 0.51% |
| Xenon Pharmaceuticals Inc |
51.64%
550,000
|
$25,333,000,000 | 0.51% |
| Rhythm Pharmaceuticals Inc. |
Opened
536,642
|
$24,669,433,000 | 0.49% |
| Repare Therapeutics Inc. |
No change
3,322,488
|
$24,254,162,000 | 0.49% |
| AbCellera Biologics Inc. |
No change
4,180,768
|
$23,872,185,000 | 0.48% |
| Vera Therapeutics Inc |
Opened
1,518,115
|
$23,348,609,000 | 0.47% |
| Pmv Pharmaceuticals Inc |
1.34%
6,475,291
|
$20,073,402,000 | 0.40% |
| Kinnate Biopharma Inc. |
98.08%
8,009,729
|
$18,983,058,000 | 0.38% |
| TELA Bio, Inc. |
6.34%
2,835,542
|
$18,771,288,000 | 0.38% |
| Aerovate Therapeutics Inc |
4.79%
756,930
|
$17,129,326,000 | 0.34% |
| Invivyd Inc |
21.68%
4,127,565
|
$16,262,606,000 | 0.33% |
| Immatics N.v |
Opened
1,543,407
|
$16,252,076,000 | 0.33% |
| Adicet Bio Inc |
11.75%
8,322,140
|
$15,728,845,000 | 0.32% |
| Alnylam Pharmaceuticals Inc |
68.30%
79,400
|
$15,197,954,000 | 0.30% |
| Krystal Biotech Inc |
Opened
103,700
|
$12,865,022,000 | 0.26% |
| Verastem Inc |
Opened
1,529,115
|
$12,446,996,000 | 0.25% |
| Corvus Pharmaceuticals Inc |
No change
6,943,654
|
$12,220,831,000 | 0.24% |
| Regeneron Pharmaceuticals, Inc. |
Opened
13,500
|
$11,856,915,000 | 0.24% |
| Amicus Therapeutics Inc |
Opened
806,000
|
$11,437,140,000 | 0.23% |
| Passage Bio Inc |
13.35%
10,124,576
|
$10,225,822,000 | 0.20% |
| Heron Therapeutics Inc |
427.92%
5,928,591
|
$10,078,605,000 | 0.20% |
| Arrowhead Pharmaceuticals In |
Opened
319,651
|
$9,781,321,000 | 0.20% |
| Uniqure Nv |
15.60%
1,347,900
|
$9,125,283,000 | 0.18% |
| Dexcom Inc |
Opened
73,200
|
$9,083,388,000 | 0.18% |
| Apollomics Inc |
Opened
8,565,456
|
$8,265,665,000 | 0.17% |
| Gilead Sciences, Inc. |
Opened
100,000
|
$8,101,000,000 | 0.16% |
| Morphic Hldg Inc |
Opened
273,400
|
$7,895,792,000 | 0.16% |
| Turnstone Biologics Corp |
Opened
3,099,265
|
$7,887,629,000 | 0.16% |
| RAPT Therapeutics, Inc. |
77.51%
281,413
|
$6,993,113,000 | 0.14% |
| InspireMD Inc |
Opened
2,133,405
|
$5,994,868,000 | 0.12% |
| X4 Pharmaceuticals, Inc. |
41.91%
7,133,515
|
$5,981,452,000 | 0.12% |
| Cullinan Oncology, LLC |
14.51%
544,848
|
$5,552,001,000 | 0.11% |
| Oric Pharmaceuticals, Inc. |
74.95%
522,968
|
$4,811,306,000 | 0.10% |
| Illumina Inc |
Opened
30,300
|
$4,218,972,000 | 0.08% |
| Ambrx Biopharma Inc. |
Opened
296,000
|
$4,215,040,000 | 0.08% |
| Nextcure Inc |
No change
2,711,013
|
$3,090,555,000 | 0.06% |
| Celldex Therapeutics Inc. |
Opened
58,800
|
$2,332,008,000 | 0.05% |
| Arcus Biosciences Inc |
61.39%
117,000
|
$2,234,700,000 | 0.04% |
| 10x Genomics, Inc. |
Opened
39,800
|
$2,227,208,000 | 0.04% |
| Fate Therapeutics Inc |
Opened
528,080
|
$1,975,019,000 | 0.04% |
| Kezar Life Sciences Inc |
8.77%
1,927,000
|
$1,825,640,000 | 0.04% |
| Bolt Biotherapeutics Inc |
99.86%
1,541,000
|
$1,725,920,000 | 0.03% |
| Ys Biopharma Co Ltd |
Opened
3,236,311
|
$1,653,755,000 | 0.03% |
| Vigil Neuroscience Inc |
9.17%
448,891
|
$1,517,252,000 | 0.03% |
| BiomX Inc |
60.57%
4,517,589
|
$1,264,925,000 | 0.03% |
| Chemomab Therapeutics Ltd |
13.07%
2,241,274
|
$1,143,050,000 | 0.02% |
| Geron Corp. |
Opened
485,000
|
$1,023,350,000 | 0.02% |
| Vir Biotechnology Inc |
Opened
101,000
|
$1,016,060,000 | 0.02% |
| Agios Pharmaceuticals Inc |
Opened
45,000
|
$1,002,150,000 | 0.02% |
| Calcimedica Inc |
Opened
297,380
|
$850,507,000 | 0.02% |
| Elevation Oncology Inc |
Opened
1,500,000
|
$805,500,000 | 0.02% |
| Acutus Med Inc |
No change
2,648,386
|
$534,709,000 | 0.01% |
| Singular Genomics Systems In |
No change
540,697
|
$248,775,000 | 0.00% |
| Bristol-Myers Squibb Co. |
Closed
2,584,900
|
$183,761,000 | |
| Pfizer Inc. |
Closed
2,599,000
|
$113,732,000 | |
| Tricida Inc |
Closed
10,280,947
|
$107,744,000 | |
| Seagen Inc |
Closed
762,600
|
$104,347,000 | |
| Mirati Therapeutics Inc |
Closed
1,418,892
|
$99,095,000 | |
| Abbvie Inc |
Closed
600,000
|
$80,526,000 | |
| Edwards Lifesciences Corp |
Closed
966,300
|
$79,845,000 | |
| Mersana Therapeutics Inc |
Closed
9,011,437
|
$60,917,000 | |
| Arcutis Biotherapeutics Inc |
Closed
2,800,000
|
$53,508,000 | |
| Guardant Health Inc |
Closed
992,400
|
$53,421,000 | |
| Bellus Health Inc |
Closed
4,634,900
|
$48,971,000 | |
| Aclaris Therapeutics Inc |
Closed
2,758,434
|
$43,418,000 | |
| Progyny Inc |
Closed
1,134,053
|
$42,028,000 | |
| Chinook Therapeutics, Inc. |
Closed
2,029,300
|
$39,896,000 | |
| Vectivbio Hldg Ag |
Closed
6,473,561
|
$38,841,000 | |
| Travere Therapeutics Inc |
Closed
1,253,130
|
$30,877,000 | |
| Biohaven Pharmactl Hldg Co L |
Closed
170,769
|
$25,815,000 | |
| 89bio Inc |
Closed
3,658,869
|
$21,185,000 | |
| Gh Research Plc |
Closed
1,622,060
|
$18,848,000 | |
| Meiragtx Hldgs Plc |
Closed
2,108,143
|
$17,729,000 | |
| Decibel Therapeutics Inc |
Closed
4,945,192
|
$17,110,000 | |
| 2seventy Bio Inc |
Closed
1,041,300
|
$15,151,000 | |
| KalVista Pharmaceuticals Inc |
Closed
1,042,000
|
$15,119,000 | |
| Verastem Inc |
Closed
17,200,000
|
$14,620,000 | |
| Rxsight Inc |
Closed
1,202,833
|
$14,434,000 | |
| Mirum Pharmaceuticals Inc |
Closed
521,891
|
$10,965,000 | |
| Cincor Pharma Inc |
Closed
314,202
|
$10,312,000 | |
| Imara Inc |
Closed
4,386,568
|
$10,001,000 | |
| Gemini Therapeutics Inc |
Closed
5,826,223
|
$9,555,000 | |
| Mereo BioPharma Group plc |
Closed
10,605,522
|
$9,132,000 | |
| Ventyx Biosciences Inc |
Closed
225,000
|
$7,855,000 | |
| Galecto Inc. |
Closed
4,090,937
|
$7,732,000 | |
| EyePoint Pharmaceuticals Inc |
Closed
970,860
|
$7,680,000 | |
| Pulmonx Corp |
Closed
435,000
|
$7,247,000 | |
| Jounce Therapeutics Inc |
Closed
2,928,900
|
$6,854,000 | |
| Spdr Ser Tr |
Closed
76,400
|
$6,060,000 | |
| Synlogic Inc |
Closed
6,029,995
|
$5,728,000 | |
| Cybin Inc |
Closed
10,453,600
|
$5,082,000 | |
| Applied Therapeutics, Inc. |
Closed
4,250,000
|
$3,953,000 | |
| Graybug Vision, Inc. |
Closed
4,163,347
|
$3,915,000 | |
| Achilles Therapeutics Plc |
Closed
1,463,251
|
$3,307,000 | |
| Amneal Pharmaceuticals Inc |
Closed
1,583,490
|
$3,199,000 | |
| Magenta Therapeutics Inc |
Closed
2,250,953
|
$3,174,000 | |
| Burning Rock Biotech Ltd |
Closed
1,282,816
|
$3,066,000 | |
| Harpoon Therapeutics, Inc. |
Closed
3,025,908
|
$2,935,000 | |
| Dyne Therapeutics, Inc. |
Closed
220,400
|
$2,799,000 | |
| Graphite Bio Inc |
Closed
848,412
|
$2,689,000 | |
| Protara Therapeutics Inc |
Closed
830,641
|
$2,459,000 | |
| LogicBio Therapeutics Inc |
Closed
8,466,783
|
$2,307,000 | |
| Pyxis Oncology Inc |
Closed
848,252
|
$1,671,000 | |
| Oncocyte Corporation |
Closed
1,882,768
|
$1,374,000 | |
| Essa Pharma Inc |
Closed
640,645
|
$1,166,000 | |
| Monte Rosa Therapeutics Inc |
Closed
117,455
|
$960,000 | |
| Aeglea BioTherapeutics Inc |
Closed
1,797,221
|
$945,000 | |
| Vor Biopharma Inc |
Closed
111,808
|
$445,000 | |
| Longboard Pharmaceuticals In |
Closed
113,500
|
$422,000 | |
| No transactions found | |||
| Showing first 500 out of 164 holdings | |||